Where will tildrakizumab be positioned in the psoriasis marketplace once approved by the FDA?
Plaque psoriasis (psoriasis vulgaris) (ICD-10 L40.0), which is commonly referred to simply as psoriasis, is the most common form of the skin disease with a prevalence of 2-3% worldwide. GlobalData estimates that the biologics total drug sales for psoriasis in 2012 was valued at $5.35 billion across the nine markets. How will tildrakizumab, currently under review by the FDA with an anticipated approval in March of 2018, compare with other drugs with a similar mechanism of action?
For our complete review of tildrakizumab :
Other Marketed and Approved Injectable Treatment Alternatives:
|Brand Name||Classification||ROA||FDA population||Maintenance Frequency||Company Name|
|adalimumab||Marketed||Humira®||tumor necrosis factor (TNF) blocker||SC||Adult||Every Other Week||AbbVie Inc|
|adalimumab-adbm||Approved||CyltezoTM||tumor necrosis factor (TNF) blocker||SC||Adult||Every Other Week||Boehringer Ingelheim Pharmaceuticals Inc|
|adalimumab-atto||Approved||AmjevitaTM||tumor necrosis factor (TNF) blocker||SC||Adult||Every Other Week||Amgen Inc|
|etanercept||Marketed||Enbrel®||tumor necrosis factor (TNF) blocker||SC||4 years and older||Every Week||Amgen Inc|
|etanercept-szzs||Approved||ErelziTM||tumor necrosis factor (TNF) blocker||SC||Adults||Every Week||Sandoz Inc|
|infliximab||Marketed||Remicade®||tumor necrosis factor (TNF) blocker||IV||Adult||Every 8 Weeks||Janssen Biotech Inc|
|infliximab-abda||Marketed||RenflexisTM||tumor necrosis factor (TNF) blocker||IV||Adult||Every 8 Weeks||Merck & Co Inc|
|infliximab-dyyb||Marketed||Inflectra®||tumor necrosis factor (TNF) blocker||IV||Adult||Every 8 Weeks||Pfizer Inc|
|infliximab-qbtx||Approved – No plans for marketing in US||IxifiTM||tumor necrosis factor (TNF) blocker||IV||Adult||Every 8 Weeks||Pfizer Inc|
|guselkumab||Marketed||Tremfya®||interleukin-23 blocker||SC||Adult||Every 8 Weeks||Janssen Biotech Inc|
|brodalumab||Marketed||SiliqTM||interleukin-17A antagonist||SC||Adult||Every 2 weeks||Valeant Pharmaceuticals International|
|ixekizumab||Marketed||Taltz®||interleukin-17A antagonist||SC||Adult||Every 4 Weeks||Eli Lilly and Co|
|secukinumab||Marketed||Cosentyx®||interleukin-17A antagonist||SC||Adults||Every 4 Weeks||Novartis Pharmaceuticals Corp|
|ustekinumab||Marketed||Stelara®||interleukin-12 and -23 antagonist||SC||12 years and older||Every 12 Weeks||Janssen Biotech Inc|
Please note: The following drugs were not included due to the lack of a FDA approved indication, moderate-to-severe plaque psoriasis: certolizumab pegol (Cimzia), golimumab (Simponi & Simponi Aria) and abatacept (Orencia). IV formulations listed above are generally reserved for more chronic, severe psoriasis.
Global Data Pharma Intelligence Center https://pharma.globaldata.com Accessed February 28, 2018
RJ Health Systems RC Reimbursement Codes https://www.reimbursementcodes.com Accessed February 21, 2018
NIH U.S. National Library of Medicine ClinicalTrails.gov https://clinicaltrials.gov/ct2/home Accessed February 20. 2018
U.S. Department of Health and Human Services. U.S. Food and Drug Administration Drugs https://www.fda.gov/Drugs/default.htm Accessed February 20. 2018
If this caught your interest, for a similar review of the rituximab biosimilar pipeline, please go to the summary blog for a link to log into and register to receive the full publication.